Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 15,303.10 8.60 0.06%
S&P 500 1,649.60 -0.91 -0.06%
NASDAQ 3,459.14 -0.27 -0.01%
Ticker Volume Price Price Delta
STOXX 50 2,764.29 -12.49 -0.45%
FTSE 100 6,654.34 -42.45 -0.63%
DAX 8,305.32 -46.66 -0.56%
Ticker Volume Price Price Delta
NIKKEI 14,612.45 128.47 0.89%
TOPIX 1,194.08 5.74 0.48%
HANG SENG 22,618.67 -51.01 -0.23%

Cipher Pharmaceuticals to present at Biotech Showcase™ 2013


Toronto Stock Exchange Symbol: DND

MISSISSAUGA, ON, Jan. 3, 2013 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) (OTC: CPHMF), announced today that Larry Andrews, President and Chief Executive Officer, is presenting at Biotech Showcase™ 2013, which is being held in San Francisco at the Wyndham Parc 55 Hotel at Union Square. Mr. Andrews will provide a corporate update on Monday, January 7, 2013 at 1:45 PM PST in the Powell Room, followed immediately by Q&A breakout session in the Balboa Room.

To learn more about Biotech Showcase™ 2013 please visit their website http://bit.ly/134duey

Cipher's presentation will be available on their website www.cipherpharma.com.

About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals (TSX: DND; OTC: CPHMF) is a growing specialty pharmaceutical company that commercializes novel formulations of successful, currently marketed molecules. Cipher's strategy is to in-license clearly differentiated products, advance them through the clinical development and regulatory approval stages, and out-license to international marketing partners. Cipher's first product is a fenofibrate formulation marketed in the United States as Lipofen®. Cipher's second product, an extended-release tramadol, is marketed in the United States as ConZip® and in Canada as Durela®. Cipher's third product, a novel formulation of the acne treatment isotretinoin, was approved by the FDA in May and was launched in the United States in Q4 2012 as Absorica™. The product was also recently approved by Health Canada and Cipher expects to launch it as Epuris™ in Canada in Q2 2013.

For more information, please visit www.cipherpharma.com.

Craig Armitage Investor Relations The Equicom Group (416) 815-0700 ext 278 (416) 815-0080 fax carmitage@equicomgroup.com

Larry Andrews President and CEO Cipher Pharmaceuticals (905) 602-5840 ext 324 (905) 602-0628 fax landrews@cipherpharma.com

SOURCE: Cipher Pharmaceuticals Inc.

To view this news release in HTML formatting, please use the following URL: http://www.newswire.ca/en/releases/archive/January2013/03/c3834.html

CO: Cipher Pharmaceuticals Inc. ST: Ontario NI: MTC HEA SHOW NP

-0- Jan/03/2013 14:00 GMT

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement